Aug 06, 2018 4:50 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 01, 2018 8:00 am EDT Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress
Jul 31, 2018 4:45 pm EDT Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
Jun 25, 2018 8:00 am EDT Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline
Jun 15, 2018 2:30 am EDT Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas
Jun 13, 2018 8:00 am EDT Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)
Jun 07, 2018 5:20 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 07, 2018 8:00 am EDT Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer